Phase I, Multiple Oral Dose Study to Evaluate the Tolerability and Pharmacokinetics of Favipiravir in Healthy Volunteers

Trial Profile

Phase I, Multiple Oral Dose Study to Evaluate the Tolerability and Pharmacokinetics of Favipiravir in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2016

At a glance

  • Drugs Favipiravir (Primary)
  • Indications Ebola virus infections; Influenza virus infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Toyama Chemical
  • Most Recent Events

    • 13 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top